Literature DB >> 19751147

Preconditioning promotes survival and angiomyogenic potential of mesenchymal stem cells in the infarcted heart via NF-kappaB signaling.

Muhammad R Afzal1, Husnain Kh Haider, Niagara Muhammad Idris, Shujia Jiang, Rafeeq P H Ahmed, Muhammad Ashraf.   

Abstract

We proposed that pharmacological manipulation of mesenchymal stem cells (MSCs) with diazoxide enhanced their survival and regenerative potential via NFkappaB regulation. MSCs preconditioned ((PC)MSCs) with diazoxide and later subjected to oxidant stress with 100 micromol/L H(2)O(2) either immediately or after 24 h exhibited higher survival (p < 0.01 vs nonpreconditioned MSCs; (Non-PC)MSCs) with concomitantly increased phosphorylation of PI3K, Akt, GSK3beta (cytoplasmic), and NF-kappaB (p65) (nuclear). Akt kinase activity was determined as a function of GSK3beta activity. Pretreatment of (PC)MSCs with Wortmannin (Wt), NEMO-binding domain (NBD), or NF-kappaB (p50) siRNA abolished NF-kappaB (p65) activity. Preconditioning increased NF-kappaB-dependent elevation of secretable growth factors associated with their paracrine effects. Inhibition of PI3K activity with Wt reduced (PC)MSCs viability at both early and 24 h time-points. However, inhibition of NF-kappaB reduced viability of (PC)MSCs only at 24 h time-point. For in vivo studies, DMEM without cells (group-1) or containing 1 x 10(6) male (Non-PC)MSCs (group-2), (PC)MSCs (group-3), (PC)MSCs pretreated with Wortmannin (group-4) or NF-kappaB decoy (group-5) were transplanted in a female rat model of acute myocardial infarction. Group-3 showed highest cell survival and growth factor expression, increased angiomyogenesis, and functional improvement. We conclude that activation of NF-kappaB by preconditioning promoted (PC)MSCs survival and angiomyogenic potential in the infarcted heart.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19751147      PMCID: PMC2834442          DOI: 10.1089/ars.2009.2755

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  24 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  Downregulation of protein kinase C inhibits activation of mitochondrial K(ATP) channels by diazoxide.

Authors:  Y Wang; E Takashi; M Xu; A Ayub; M Ashraf
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

3.  The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation.

Authors:  Alexander Hoffmann; Andre Levchenko; Martin L Scott; David Baltimore
Journal:  Science       Date:  2002-11-08       Impact factor: 47.728

Review 4.  The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus.

Authors:  D M Rothwarf; M Karin
Journal:  Sci STKE       Date:  1999-10-26

5.  NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis.

Authors:  F Kühnel; L Zender; Y Paul; M K Tietze; C Trautwein; M Manns; S Kubicka
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

6.  Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.

Authors:  Catalin Toma; Mark F Pittenger; Kevin S Cahill; Barry J Byrne; Paul D Kessler
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

7.  Mitochondrial K(ATP) channel as an end effector of cardioprotection during late preconditioning: triggering role of nitric oxide.

Authors:  Y Wang; M Kudo; M Xu; A Ayub; M Ashraf
Journal:  J Mol Cell Cardiol       Date:  2001-11       Impact factor: 5.000

8.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.

Authors:  Christoph Becker; Massimo C Fantini; Christoph Schramm; Hans A Lehr; Stefan Wirtz; Alexei Nikolaev; Jürgen Burg; Susanne Strand; Ralf Kiesslich; Samuel Huber; Hiroaki Ito; Norihiro Nishimoto; Kazuyuki Yoshizaki; Tadamitsu Kishimoto; Peter R Galle; Manfred Blessing; Stefan Rose-John; Markus F Neurath
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

9.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.

Authors:  C E Murry; R B Jennings; K A Reimer
Journal:  Circulation       Date:  1986-11       Impact factor: 29.690

10.  Nuclear factor-kappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction.

Authors:  Arunima Misra; Sandra B Haudek; Pascal Knuefermann; Jesus G Vallejo; Zhijian J Chen; Lloyd H Michael; Natarajan Sivasubramanian; Eric N Olson; Mark L Entman; Douglas L Mann
Journal:  Circulation       Date:  2003-12-15       Impact factor: 29.690

View more
  37 in total

Review 1.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

2.  Oxygen cycling in conjunction with stem cell transplantation induces NOS3 expression leading to attenuation of fibrosis and improved cardiac function.

Authors:  Mahmood Khan; Sarath Meduru; Rajan Gogna; Esha Madan; Lucas Citro; Muthulakshmi L Kuppusamy; Muzzammil Sayyid; Mahmoud Mostafa; Robert L Hamlin; Periannan Kuppusamy
Journal:  Cardiovasc Res       Date:  2011-10-19       Impact factor: 10.787

3.  Freeze-dried rat bone marrow mesenchymal stem cell paracrine factors: a simplified novel material for skin wound therapy.

Authors:  Yan Peng; Min Xuan; Jiping Zou; Hongwei Liu; Ziyuan Zhuo; Yu Wan; Biao Cheng
Journal:  Tissue Eng Part A       Date:  2014-12-11       Impact factor: 3.845

Review 4.  Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.

Authors:  Sudhir H Ranganath; Oren Levy; Maneesha S Inamdar; Jeffrey M Karp
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

5.  Matrix composition and mechanics direct proangiogenic signaling from mesenchymal stem cells.

Authors:  Amr A Abdeen; Jared B Weiss; Junmin Lee; Kristopher A Kilian
Journal:  Tissue Eng Part A       Date:  2014-05-12       Impact factor: 3.845

6.  Aggregation of human mesenchymal stem cells enhances survival and efficacy in stroke treatment.

Authors:  Xuegang Yuan; Jens T Rosenberg; Yijun Liu; Samuel C Grant; Teng Ma
Journal:  Cytotherapy       Date:  2019-09-17       Impact factor: 5.414

7.  Pharmacological preconditioning for short-term ex vivo expansion of human umbilical cord blood hematopoietic stem cells by filgrastim.

Authors:  Nikolaos G Grigoriadis; Ioannis G Grigoriadis; Sofia Markoula; Minas Paschopoulos; Konstantinos Zikopoulos; Panagiotis Gr Apostolakopoulos; Ioannis S Vizirianakis; Ioannis Georgiou
Journal:  Am J Stem Cells       Date:  2016-05-15

Review 8.  Cell based therapies for ischemic stroke: from basic science to bedside.

Authors:  Xinfeng Liu; Ruidong Ye; Tao Yan; Shan Ping Yu; Ling Wei; Gelin Xu; Xinying Fan; Yongjun Jiang; R Anne Stetler; George Liu; Jieli Chen
Journal:  Prog Neurobiol       Date:  2013-12-12       Impact factor: 11.685

Review 9.  A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies.

Authors:  Pardis Saeedi; Raheleh Halabian; Abbas Ali Imani Fooladi
Journal:  Stem Cell Investig       Date:  2019-09-25

10.  Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.

Authors:  Muhammad Ali; Azra Mehmood; Muhammad Sohail Anjum; Moazzam Nazir Tarrar; Shaheen N Khan; Sheikh Riazuddin
Journal:  Mol Cell Biochem       Date:  2015-09-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.